Abstract
The five-year survival rate of esophageal cancer patients is less than 20%. This may be due to increased resistance (acquired or intrinsic) of tumor cells to chemo/radiotherapies, often caused by aberrant cell cycle, deregulated apoptosis, increases in growth factor signaling pathways, and/or changes in the proteome network. In addition, deregulation in non-coding RNA-mediated signaling pathways may contribute to resistance to therapies. At the molecular level, these resistance factors have now been linked to various microRNA (miRNAs), which have recently been shown to control cell development, differentiation and neoplasia. The increased stability and dysregulated expression of miRNAs have been associated with increased resistance to various therapies in several cancers, including esophageal cancer. Therefore, miRNAs represent the next generation of molecules with tremendous potential as biomarkers and therapeutic targets. However, detailed studies on miRNA-based therapeutic interventions are still in their infancy. Hence, in this review, we have summarized the current status of microRNAs in dictating the resistance/sensitivity of tumor cells to chemotherapy and radiotherapy. In addition, we have discussed various strategies to increase radiosensitivity, including targeted therapy, and the use of miRNAs as radiosensitive/radioresistance biomarkers for esophageal cancer in the clinical setting.
| Language | English (US) |
|---|---|
| Pages | 148-157 |
| Number of pages | 10 |
| Journal | Biochimie |
| Volume | 156 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Esophageal cancer
- microRNAs
- Radioresistance
- Radiosenstivity
- Tumor resistance
ASJC Scopus subject areas
- Biochemistry
Cite this
Stabilization of miRNAs in esophageal cancer contributes to radioresistance and limits efficacy of therapy. / Malhotra, Akshay; Sharma, Uttam; Puhan, Shyamly; Chandra Bandari, Naga; Kharb, Anjali; Arifa, P. P.; Thakur, Lovlesh; Prakash, Hridayesh; Vasquez, Karen; Jain, Aklank.
In: Biochimie, Vol. 156, 01.01.2019, p. 148-157.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Stabilization of miRNAs in esophageal cancer contributes to radioresistance and limits efficacy of therapy
AU - Malhotra, Akshay
AU - Sharma, Uttam
AU - Puhan, Shyamly
AU - Chandra Bandari, Naga
AU - Kharb, Anjali
AU - Arifa, P. P.
AU - Thakur, Lovlesh
AU - Prakash, Hridayesh
AU - Vasquez, Karen
AU - Jain, Aklank
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The five-year survival rate of esophageal cancer patients is less than 20%. This may be due to increased resistance (acquired or intrinsic) of tumor cells to chemo/radiotherapies, often caused by aberrant cell cycle, deregulated apoptosis, increases in growth factor signaling pathways, and/or changes in the proteome network. In addition, deregulation in non-coding RNA-mediated signaling pathways may contribute to resistance to therapies. At the molecular level, these resistance factors have now been linked to various microRNA (miRNAs), which have recently been shown to control cell development, differentiation and neoplasia. The increased stability and dysregulated expression of miRNAs have been associated with increased resistance to various therapies in several cancers, including esophageal cancer. Therefore, miRNAs represent the next generation of molecules with tremendous potential as biomarkers and therapeutic targets. However, detailed studies on miRNA-based therapeutic interventions are still in their infancy. Hence, in this review, we have summarized the current status of microRNAs in dictating the resistance/sensitivity of tumor cells to chemotherapy and radiotherapy. In addition, we have discussed various strategies to increase radiosensitivity, including targeted therapy, and the use of miRNAs as radiosensitive/radioresistance biomarkers for esophageal cancer in the clinical setting.
AB - The five-year survival rate of esophageal cancer patients is less than 20%. This may be due to increased resistance (acquired or intrinsic) of tumor cells to chemo/radiotherapies, often caused by aberrant cell cycle, deregulated apoptosis, increases in growth factor signaling pathways, and/or changes in the proteome network. In addition, deregulation in non-coding RNA-mediated signaling pathways may contribute to resistance to therapies. At the molecular level, these resistance factors have now been linked to various microRNA (miRNAs), which have recently been shown to control cell development, differentiation and neoplasia. The increased stability and dysregulated expression of miRNAs have been associated with increased resistance to various therapies in several cancers, including esophageal cancer. Therefore, miRNAs represent the next generation of molecules with tremendous potential as biomarkers and therapeutic targets. However, detailed studies on miRNA-based therapeutic interventions are still in their infancy. Hence, in this review, we have summarized the current status of microRNAs in dictating the resistance/sensitivity of tumor cells to chemotherapy and radiotherapy. In addition, we have discussed various strategies to increase radiosensitivity, including targeted therapy, and the use of miRNAs as radiosensitive/radioresistance biomarkers for esophageal cancer in the clinical setting.
KW - Esophageal cancer
KW - microRNAs
KW - Radioresistance
KW - Radiosenstivity
KW - Tumor resistance
UR - http://www.scopus.com/inward/record.url?scp=85055272739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055272739&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2018.10.006
DO - 10.1016/j.biochi.2018.10.006
M3 - Review article
VL - 156
SP - 148
EP - 157
JO - Biochimie
T2 - Biochimie
JF - Biochimie
SN - 0300-9084
ER -